Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration

被引：0
作者：
Monica Dalal
Naima Jacobs-El
Benjamin Nicholson
Jingsheng Tuo
Emily Chew
Chi-Chao Chan
Robert Nussenblatt
Frederick Ferris
Catherine Meyerle
机构：
[1] National Eye Institute,Laboratory of Immunology
[2] National Institutes of Health,Division of Epidemiology and Clinical Applications
[3] National Eye Institute,undefined
[4] National Institutes of Health,undefined
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2013年 / 251卷
关键词：
Akt/mTOR; Choroidal neovascularization; Neovascular age-related macular degeneration; Palomid 529;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2705 / 2709
页数：4
相关论文
共 50 条
  • [41] The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
    Musial-Kopiejka, Magdalena
    Polanowska, Katarzyna
    Dobrowolski, Dariusz
    Krysik, Katarzyna
    Wylegala, Edward
    Grabarek, Beniamin Oskar
    Lyssek-Boron, Anita
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (04)
  • [42] Treatment of neovascular age-related macular degeneration: past, present and future directions
    Smith, Bradley T.
    Joseph, Daniel P.
    Grand, M. Gilbert
    CURRENT OPINION IN OPHTHALMOLOGY, 2007, 18 (03) : 240 - 244
  • [43] EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS
    Rahimy, Ehsan
    Ying, Gui-Shuang
    Pan, Wei
    Hsu, Jason
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (04): : 636 - 647
  • [44] Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater
    Cornish, Elisa E.
    Vuong Nguyen
    Young, Stephanie
    Fraser-Bell, Samantha
    Guymer, Robyn
    Squirrell, David
    Barthelmes, Daniel
    Gillies, Mark C.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 49 (06) : 570 - 578
  • [45] Emerging Treatment Modalities for Neovascular Age-Related Macular Degeneration: A Systematic Overview
    Balatsoukas, Dionysis D.
    Tsaousis, Konstantinos T.
    Boboridis, Konstadinos G.
    Konstas, Anastasios G.
    Topouzis, Fotis
    ADVANCES IN THERAPY, 2022, 39 (01) : 5 - 32
  • [46] Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
    ElSheikh, Reem H.
    Chauhan, Muhammad Z.
    Sallam, Ahmed B.
    BIOMOLECULES, 2022, 12 (11)
  • [47] Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
    Tan, Colin S.
    Ngo, Wei Kiong
    Chay, Isaac W.
    Ting, Dominic S.
    Sadda, SriniVas R.
    CLINICAL OPHTHALMOLOGY, 2022, 16 : 917 - 933
  • [48] Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration
    Frampton, James E.
    DRUGS & AGING, 2013, 30 (05) : 331 - 358
  • [49] High dose aflibercept treatment in naive neovascular age-related macular degeneration
    Acar, Nur
    Pehlivanoglu, Seren
    INTERNATIONAL OPHTHALMOLOGY, 2025, 45 (01)
  • [50] Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events
    Weinstein, Orly
    Abu Tailakh, Muhammad
    Lifshitz, Tova
    Novack, Victor
    Levy, Jaime
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2020, 30 (01) : 66 - 71
12345